Global Pharma Growth Poised To Moderate, IQVIA Predicts
Historically low US brand price growth is one factor in a general slowdown in the annual growth rate of the global pharmaceutical market from 2019 through 2023, IQVIA forecasts in a new trends report.
You may also be interested in...
Global spending on medicines will continue to increase through 2024, but at a lower rate than the previous five years due to the impact of discounts, rebates and patent expirations.
Pharma is facing a big headwind in 2019 in the form of diminished drug pricing power. The pricing trend puts net drug prices squarely in the red for most large pharma manufacturers, but US lawmakers aren't likely to be reassured heading into an upcoming hearing on drug pricing.
Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.